Hematologic Oncology | Specialty

Relationship Between TA-TMA Development and GVHD

April 8th 2021

The panel considers the development, morbidity, and survival of transplant-associated thrombotic microangiopathy associated with GVHD (graft-versus-host disease).

Weight-Based Dosing With Narsoplimab Is Recommended in HSCT-TMA

April 7th 2021

Pharmacodynamic and pharmacokinetic modeling of the investigational MASP-2 inhibitor narsoplimab supported a weight-based dosing method for patients with hematopoietic stem cell transplant–associated thrombotic microangiopathy.

Selinexor, Bortezomib, and Dexamethasone Combination Proves Effective for Myeloma

April 7th 2021

In December 2020, the FDA approved selinexor in combination with the proteasome inhibitor bortezomib and dexamethasone for patients with MM who have received at least 1 prior therapy.

A Review of Pacritinib and PACIFICA Data

April 7th 2021

Srdan Verstovsek, MD, PhD, briefly reviews the role of pacritinib in patients with myelofibrosis as well as the PACIFICA study.

Mitigating Peripheral Neuropathy Is Still Focus of Ongoing Research in Hodgkin Lymphoma

April 7th 2021

Mendel Goldfinger, MD, discusses some of the key points of the ECHELON-1 trial data.

The Role of Transplant in Myelofibrosis

April 7th 2021

Experts discuss the role of transplant and evaluating options in patients with myelofibrosis. 

Searching for Molecular Targets in Myeloid Malignancies and Beyond

April 6th 2021

Ulrich Steidl, MD, PhD, discusses translational research efforts that have been made with targeting leukemia stem cells and ongoing clinical trials that are examining novel therapeutic targets in myeloid malignancies and beyond.

D-VCd Rises as the New Standard of Care in Newly Diagnosed AL Amyloidosis

April 6th 2021

Jonathan L. Kaufman, MD, discusses the significance of subcutaneous D-VCd in the treatment of patients with AL amyloidosis, remaining questions with the approach, and emerging strategies for those with high-risk cardiac features.

Genomic Sequencing Identifies Pediatric Therapy-Related Myeloid Neoplasm Defining Variants Prior to Clinical Presentation

April 5th 2021

Somatic KMT2A rearrangements, RAS/MAPK mutations, RUNX1 and TP53 alterations, and MECOM overexpression were all found to be common oncogenic drivers of pediatric therapy-related myeloid neoplasms, arising predominantly after exposure to cytotoxic therapy and identifiable at least 1 year prior to morphologic evidence of neoplasm.

Treating Follicular Lymphoma With Early Progression

April 5th 2021

Approaches to sequencing therapy for patients with follicular lymphoma who experience progression of disease within 24 months (POD24).